18 September 2014

IPO Affimed on NASDAQ

De Brauw Blackstone Westbroek advised Affimed on its IPO on the NASDAQ Global Market. Affimed will offer a total of 9,200,000 shares, with the deal pricing on 12 September 2014 at USD 7,00 per share.

Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies.

 

De Brauw acted as Dutch counsel to Affimed and Constantijn Voogt was lead partner.

 

 

We keep track of you on our site with cookies, in order to offer the basic functionality of the website and generate user statistics on an anonymous basis to make our website more user-friendly. We do not use or share your data with third parties for advertising purposes.
Accept cookiesChange cookiesClick here for more information about our cookies.